MedTrace Logo

Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

NCT06573593 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-08-27

No results posted yet for this study

Summary

The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disease characteristics and patients profiles that are considered good candidates for JAKi in the daily practice. Furthermore, we intended to investigate the efficacy and safety of JAK Inhibitors in patients With AA, as well as to provide clinical evidence for the clinicians and patients when they formulate individualized treatment plans.

Conditions

Interventions

DRUG

Tofacitinib

In the real-world settings, patients with AA treated with tofacitinib.

DRUG

Baricitinib

In the real-world settings, patients with AA treated with Baricitinib.

DRUG

Ruxolitinib

In the real-world settings, patients with AA treated with Ruxolitinib.

DRUG

Upadacitinib

In the real-world settings, patients with AA treated with Upadacitinib.

DRUG

Abrocitinib

In the real-world settings, patients with AA treated with Abrocitinib.

DRUG

Ritlecitinib

In the real-world settings, patients with AA treated with Ritlecitinib.

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Xianjie Wu, Ph.D · Second Affiliated Hospital, School of Medicine, Zhejiang University

Eligibility

Min Age
2 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-29
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06573593 on ClinicalTrials.gov